These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19200016)

  • 1. Gene and cell therapy for prion diseases.
    Relaño-Ginés A; Gabelle A; Lehmann S; Milhavet O; Crozet C
    Infect Disord Drug Targets; 2009 Feb; 9(1):58-68. PubMed ID: 19200016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
    Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
    Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prion protein self-interactions: a gateway to novel therapeutic strategies?
    Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
    Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tackling prion diseases: a review of the patent landscape.
    Zattoni M; Legname G
    Expert Opin Ther Pat; 2021 Dec; 31(12):1097-1115. PubMed ID: 34134584
    [No Abstract]   [Full Text] [Related]  

  • 5. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease.
    White MD; Farmer M; Mirabile I; Brandner S; Collinge J; Mallucci GR
    Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10238-43. PubMed ID: 18632556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice.
    Pfeifer A; Eigenbrod S; Al-Khadra S; Hofmann A; Mitteregger G; Moser M; Bertsch U; Kretzschmar H
    J Clin Invest; 2006 Dec; 116(12):3204-10. PubMed ID: 17143329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for eliminating PrP(c) as substrate for prion conversion and for enhancing PrP(Sc) degradation.
    Gilch S; Nunziante M; Ertmer A; Schätzl HM
    Vet Microbiol; 2007 Aug; 123(4):377-86. PubMed ID: 17493775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the anti-prion mechanism of four different anti-prion compounds, anti-PrP monoclonal antibody 44B1, pentosan polysulfate, chlorpromazine, and U18666A, in prion-infected mouse neuroblastoma cells.
    Yamasaki T; Suzuki A; Hasebe R; Horiuchi M
    PLoS One; 2014; 9(9):e106516. PubMed ID: 25181483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.
    Meier P; Genoud N; Prinz M; Maissen M; Rülicke T; Zurbriggen A; Raeber AJ; Aguzzi A
    Cell; 2003 Apr; 113(1):49-60. PubMed ID: 12679034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aptamers against prion proteins and prions.
    Gilch S; Schätzl HM
    Cell Mol Life Sci; 2009 Aug; 66(15):2445-55. PubMed ID: 19396399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Fluorescent Oligothiophene-Bis-Triazine ligand interacts with PrP fibrils and detects SDS-resistant oligomers in human prion diseases.
    Imberdis T; Ayrolles-Torro A; Duarte Rodrigues A; Torrent J; Alvarez-Martinez MT; Kovacs GG; Verdier JM; Robitzer M; Perrier V
    Mol Neurodegener; 2016 Jan; 11():11. PubMed ID: 26809712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of antibody fragments for immunotherapy of prion diseases.
    Campana V; Zentilin L; Mirabile I; Kranjc A; Casanova P; Giacca M; Prusiner SB; Legname G; Zurzolo C
    Biochem J; 2009 Mar; 418(3):507-15. PubMed ID: 19000036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNAi: a novel strategy for the treatment of prion diseases.
    Kong Q
    J Clin Invest; 2006 Dec; 116(12):3101-3. PubMed ID: 17143323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy in prion diseases: from molecular and cellular biology to therapeutic targets.
    Krammer C; Vorberg I; Schätzl HM; Gilch S
    Infect Disord Drug Targets; 2009 Feb; 9(1):3-14. PubMed ID: 19200010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel regulators of PrP
    Colini Baldeschi A; Vanni S; Zattoni M; Legname G
    Expert Opin Ther Targets; 2020 Aug; 24(8):759-776. PubMed ID: 32631090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation.
    Perrier V; Solassol J; Crozet C; Frobert Y; Mourton-Gilles C; Grassi J; Lehmann S
    J Neurochem; 2004 Apr; 89(2):454-63. PubMed ID: 15056288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prion's elusive reason for being.
    Aguzzi A; Baumann F; Bremer J
    Annu Rev Neurosci; 2008; 31():439-77. PubMed ID: 18558863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanisms of prion transmission].
    Sakaguchi S
    Nihon Rinsho; 2007 Aug; 65(8):1391-5. PubMed ID: 17695274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prion protein functions and dysfunction in prion diseases.
    Sakudo A; Ikuta K
    Curr Med Chem; 2009; 16(3):380-9. PubMed ID: 19149584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The suppression of prion propagation using poly-L-lysine by targeting plasminogen that stimulates prion protein conversion.
    Ryou C; Titlow WB; Mays CE; Bae Y; Kim S
    Biomaterials; 2011 Apr; 32(11):3141-9. PubMed ID: 21288569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.